Dactinomycin - Rasna Therapeutics

Drug Profile

Dactinomycin - Rasna Therapeutics

Alternative Names: Act D - Rasna Therapeutics; Actinomycin D; RASP-101

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rasna Therapeutics
  • Class Antineoplastics; Cytostatic antibiotics; Small molecules
  • Mechanism of Action RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia

Most Recent Events

  • 03 Jan 2018 Updated efficacy data from a phase II trial in Acute myeloid leukaemia (Recurrent, Second-line therapy or greater) released by Rasna Therapeutics
  • 17 May 2017 Rasna Therapeutics has patent protection for RASP 101 (Rasna Therapeutics' website, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top